US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

HORIZON KINETICS MEDICAL ETF

35.06

0.0000

Volume:14

Turnover:492.98

Market Cap:16.48M

PE:- -

High:35.06

Open:35.06

Low:35.06

Close:35.06

52wk High:37.90

52wk Low:28.87

Shares:469.95K

Float Shares:469.95K

Volume Ratio:0.02

T/O Rate:0.00%

Dividend:0.41

Dividend Rate:1.17%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Abbvie - Declares Qtrly Cash Dividend of $1.73 Per Share

THOMSON REUTERS

AbbVie’s Eye Implant Study Delivers Fresh Real‑World Clarity for Investors

Wachtell Dealmaker Jumps to Linklaters to Bolster US Buildout

Johnson & Johnson Announces R$ 0.3 Per Unit Dividend for 3Q 2026

Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD

Eli Lilly is Maintained at Reduce by HSBC

Eli Lilly’s GLP-1 Windfall to Fund Push into Women’s Health - Bloomberg News

Novartis shareholder calls for board changes, Reuters reports

AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study

MT Newswires Live

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

Abbvie - Atogepant Safety Results Consistent with Known Profile; no New Safety Signals

THOMSON REUTERS

Abbvie - Atogepant Meets Primary and All Eight Ranked Secondary Endpoints in Phase 3 Luna Study

THOMSON REUTERS

Abbvie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

THOMSON REUTERS

Abbvie - Atogepant Shows Significant Improvements Across Multiple Endpoints Versus Placebo

THOMSON REUTERS

Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX

Market Chatter: Novartis Shareholder Urges Board Changes After Trial Failures

MT Newswires Live

Johnson & Johnson Receives Ce Marking for Acuvue Oasys Max Reusable Contact Lenses

THOMSON REUTERS

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

Alkermes Announces Launch of 9TH Annual Alkermes Pathways Research Awards® Program

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/MEDX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MEDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","market":"US","secType":"STK","nameCN":"HORIZON KINETICS MEDICAL ETF","latestPrice":35.0604,"timestamp":1789136271582,"preClose":35.0604,"halted":0,"volume":14,"delay":0,"changeRate":0,"floatShares":469946,"shares":469946,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"09-11 11:18:52 EDT","open":35.0604,"high":35.0604,"low":35.0604,"amount":492.98046,"amplitude":0,"askPrice":35.08,"askSize":700,"bidPrice":34.88,"bidSize":500,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789156800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":35.0604,"sharesOutstanding":569946,"nav":35.21,"aum":16546798.66,"dividendRate":0.0117,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":35.2396,"preClose":35.0604,"latestTime":"16:10 EDT","volume":6,"amount":210.2016,"timestamp":1789071007727,"change":0.1792,"changeRate":0.005111,"amplitude":0},"volumeRatio":0.01936},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","floatShares":469946,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.01936,"shares":469946,"dividePrice":0.4102,"high":35.0604,"amplitude":0,"preClose":35.0604,"low":35.0604,"week52Low":28.8652,"pbRate":"--","week52High":37.9,"institutionHeld":0,"latestPrice":35.0604,"committee":-0.166667,"eps":0,"divideRate":0.0117,"volume":14,"delay":0,"ttmEps":0,"open":35.0604,"prevYearClose":33.2024,"prevWeekClose":36.6906,"prevMonthClose":36.417,"prevQuarterClose":36.7138,"fiveDayClose":37.0834,"twentyDayClose":35.9599,"sixtyDayClose":34.1895},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MEDX\",params:#limit:5,,,undefined,":[{"date":"2025-12-23","symbol":"MEDX","amount":0.4088,"announcedDate":"2025-12-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-23","defaultRemindTime":1766500200000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-23","currency":"USD","dateTimestamp":1766466000000,"payDate":"2025-12-24"},{"date":"2024-12-24","symbol":"MEDX","amount":0.502335,"announcedDate":"2024-12-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-24","defaultRemindTime":1735050600000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-24","currency":"USD","dateTimestamp":1735016400000,"payDate":"2024-12-26"},{"date":"2023-12-27","symbol":"MEDX","amount":1.379798,"announcedDate":"2023-12-26","type":"dividend","market":"US","newRecordDate":"2023-12-28","defaultRemindTime":1703687400000,"name":"HORIZON KINETICS MEDICAL ETF","recordDate":"2023-12-29","payableDate":"2023-12-28","currency":"USD","dateTimestamp":1703653200000,"payDate":"2023-12-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MEDX\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-27","recordDate":"2023-12-28","paymentDate":"2023-12-29","value":1.379798,"currency":"USD"},{"executeDate":"2024-12-24","recordDate":"2024-12-24","paymentDate":"2024-12-26","value":0.502335,"currency":"USD"},{"executeDate":"2025-12-23","recordDate":"2025-12-23","paymentDate":"2025-12-24","value":0.4088,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MEDX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MEDX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666590101","title":"Abbvie - Declares Qtrly Cash Dividend of $1.73 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2666590101","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666590101?lang=en_us&edition=fundamental","pubTime":"2026-09-11 02:18","pubTimestamp":1789064315,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nFWN4520NY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2237443622.USD","LU1983299246.USD","FTXH","LU2087621335.USD","LU0868494708.USD","LU1093756325.SGD","LU2468319806.SGD","IE0002270589.USD","LU1244550577.SGD","LU1162221912.USD","LU0310800379.SGD","IE000BZT7R73.USD","VHT","LU0069063385.USD","LU1496350502.SGD","IE00BLSP4239.USD","BK4581","GLAM","IXJ","JDOC","SG9999015945.SGD","IE000WAW04H5.SGD","MEDX","PPH","LU0985320562.USD","LU1057294990.SGD","IYH","RXL","PJP","FHLC","LU2112291526.USD","LU0320765646.SGD","LU1496350171.SGD","LU2125909593.SGD","BK4550","LU1074936037.SGD","BK4139","LU1732799900.SGD","XLV","BK4588","LU0310799852.SGD","ABBV","LU2237443465.HKD","SG9999015978.USD","TRUH","LU0949170772.SGD","LU0511384066.AUD","AGNG","LU1236620834.HKD","LU1267930573.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666973105","title":"AbbVie’s Eye Implant Study Delivers Fresh Real‑World Clarity for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2666973105","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666973105?lang=en_us&edition=fundamental","pubTime":"2026-09-11 00:30","pubTimestamp":1789057812,"startTime":"0","endTime":"0","summary":"Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie is reporting new data from an observational eye study in adults with dia...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abbvies-eye-implant-study-delivers-fresh-realworld-clarity-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abbvies-eye-implant-study-delivers-fresh-realworld-clarity-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","XLV","LU1061106388.HKD","IE00BJJMRZ35.SGD","LU0726765562.USD","LU0795875169.SGD","RXL","PJP","PPH","IYH","IE00BJT1NW94.SGD","LU0738911758.USD","LU0820561818.USD","LU0203345920.USD","ABBV","LU1003077747.HKD","FTXH","LU0234570918.USD","LU1244550221.USD","LU2089284900.SGD","LU0868494617.USD","LU0256863811.USD","IE00BDGV0183.EUR","AGNG","IXJ","ISBC","LU0057025933.USD","LU1839511570.USD","TRUH","IE00BBT3K403.USD","JDOC","LU1496350171.SGD","LU2347655156.SGD","MEDX","IE0002141913.USD","LU0320765646.SGD","LU0256863902.USD","LU2433249047.HKD","LU0211328371.USD","LU1074936037.SGD","LU2468319806.SGD","IE000F7OJYX1.SGD","LU2237443895.HKD","LU1585245621.USD","GLAM","VHT","LU0417517546.SGD","IE00B4R5TH58.HKD","FHLC","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666659414","title":"Wachtell Dealmaker Jumps to Linklaters to Bolster US Buildout","url":"https://stock-news.laohu8.com/highlight/detail?id=2666659414","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666659414?lang=en_us&edition=fundamental","pubTime":"2026-09-10 23:04","pubTimestamp":1789052640,"startTime":"0","endTime":"0","summary":"Wachtell dealmaker jumps to Linklaters to bolster US buildoutSept 10 (Reuters)-Law firm Linklaters said on Thursday that it has hired longtime partner Mark Gordon from Wachtell, Lipton, Rosen & Katz, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nL6N4520WA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0210536198.USD","IYH","XLV","LU0496365809.HKD","IE00BDGV0183.EUR","LU1084165304.USD","BMED","LU0689472784.USD","RXL","IE00BVYPNW00.USD","GDOC","LU1355424745.HKD","LU1989771016.USD","LU2293690082.USD","LU0053666078.USD","IHE","LU1829250122.USD","JDOC","LU1880407215.USD","FTXH","LU0466842654.USD","LU2089284900.SGD","IE00B3PB1722.GBP","JHX","03165","LU1323610961.USD","LU2430703095.HKD","PJP","LU2089283258.USD","MEDX","LU0708994859.HKD","LU0072461881.USD","LU2112291526.USD","JNJ","LU2750360997.AUD","LU0960981461.USD","FHLC","LU0972486137.USD","IE000SO60NU8.SGD","IXJ","LU0211326839.USD","VHT","IE00B4R5TH58.HKD","LU1291159041.SGD","LU0077335932.USD","IE00BLSP4452.SGD","LU1814569148.SGD","LU0949170426.SGD","AZN.UK","TRUH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666591236","title":"Johnson & Johnson Announces R$ 0.3 Per Unit Dividend for 3Q 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2666591236","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666591236?lang=en_us&edition=fundamental","pubTime":"2026-09-10 22:31","pubTimestamp":1789050684,"startTime":"0","endTime":"0","summary":"Johnson & Johnson announces R$ 0.3 per unit dividend for 3Q 2026Johnson & Johnson declared a dividend of R$ 0.3 per unit for the third quarter of 2026.Last day to trade with dividend rights is Aug. 24","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL8Bmdh0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B1BXHZ80.USD","BMED","RXL","LU0683600562.USD","LU1066051225.USD","PJP","LU2023250330.USD","FHLC","LU2750360997.AUD","LU2750360641.GBP","LU0426417589.USD","IE0002141913.USD","LU1057294990.SGD","LU2602419157.SGD","LU1506573853.SGD","LU0289739699.SGD","IE00B19Z3B42.SGD","IYH","LU2133065610.SGD","MEDX","IE00BVYPNV92.GBP","SG9999001440.SGD","XLV","GDOC","IXJ","VHT","LU0345769128.USD","IE000M9KFDE8.USD","LU1280957306.USD","LU2471134952.CNY","LU0640476718.USD","LU0795875086.SGD","LU2471134879.HKD","LU1267930813.SGD","LU1244550494.USD","IE00BVYPNW00.USD","JDOC","IE000SO60NU8.SGD","IE00BFXG1179.USD","TRUH","LU1074936037.SGD","IHE","LU0053666078.USD","BK4007","FTXH","JNJ","LU2430703251.USD","LU0320765646.SGD","IE00B3T34201.USD","LU0345769631.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666910405","title":"Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2666910405","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666910405?lang=en_us&edition=fundamental","pubTime":"2026-09-10 22:25","pubTimestamp":1789050337,"startTime":"0","endTime":"0","summary":"Optimi Health (OPTH) announces plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for individuals with maj...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/optimi-health-to-initiate-phase-2-trial-of-psilocybin-assisted-therapy-for-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/optimi-health-to-initiate-phase-2-trial-of-psilocybin-assisted-therapy-for-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","OPTH","HYLG","MEDX","ABVC","BK4007","IDNA","BK4139","PSIL","BBC","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666066599","title":"Eli Lilly is Maintained at Reduce by HSBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2666066599","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666066599?lang=en_us&edition=fundamental","pubTime":"2026-09-10 22:06","pubTimestamp":1789049160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LLY/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WDNA","LU2168564495.EUR","LU0289739699.SGD","LU0385154629.USD","LU0964807845.USD","LU1366192091.USD","LU2112291526.USD","CANC","FTXH","ILDR","LU0823416689.USD","IE00BFSS8Q28.SGD","LU1814569148.SGD","SG9999018865.SGD","SGXZ99366536.SGD","LU1868836914.USD","LU2357305700.SGD","SGXZ57979304.SGD","IE00BJJMRX11.SGD","IE00BKDWB100.SGD","LU2089283258.USD","IE0005OL40V9.USD","IE0004445015.USD","SG9999015986.USD","IE00B4JS1V06.HKD","LU0672654240.SGD","LU0889565916.HKD","LU1868836757.USD","IE00BWXC8680.SGD","LU0882574055.USD","MEDX","LU1061106388.HKD","LU2461242641.AUD","PPH","TRUH","LU2462591350.SGD","LU2023250504.SGD","IYH","LU1804176565.USD","LU1551013425.SGD","LU2324357040.USD","LU2750360641.GBP","LU0466842654.USD","LU1623119135.USD","HRTS","LU2756315318.SGD","LU0198837287.USD","LU2168564222.USD","LU2237438978.USD","SG9999014906.USD","LLII","LU2456880835.USD","LU1093756325.SGD","LU2236285917.USD","BK4585","LU2237443549.SGD","LU2168564149.EUR","IHE","LU0256863811.USD","LU1974910355.USD","LU1868836591.USD","BK4516","BK4534","LLY","LU2552382132.HKD","SGXZ31699556.SGD","LU0096364046.USD","LU0234572021.USD","LU0203201768.USD","LU2360106947.USD","LU2264538146.SGD","LU2746668461.USD","LU2471134879.HKD","SG9999013999.USD","LU1979441026.SGD","LU0320765059.SGD","LLYX","LU2108987350.USD","LU2746668974.SGD","LU0097036916.USD","LU1280957306.USD","LU2265009873.SGD","LU0203202063.USD","LU0316494557.USD","LU2417539215.USD","LU2552382058.USD","SG9999014914.USD","LU0689472784.USD","LU1983299246.USD","LU2211815571.USD","IE00BK4W5M84.HKD","LU1712237335.SGD","IE0001KFT4U8.USD","LU2271345857.HKD","LU2213496289.HKD","LU0323591593.USD","OZEM","LU2089984988.USD","LU0471298694.HKD","LU0456855351.SGD","LU0345770993.USD","LU1720051108.HKD","LU0943347566.SGD","LU1323610961.USD","IE0004445239.USD","CURE","LU1145028129.USD","LU2491050154.USD","LU0471298777.SGD","XLV","GB00BDT5M118.USD","LU1629891620.HKD","SGXZ51526630.SGD","LLYZ","LU0133085943.USD","TMED","VHT","FHLC","IE00BFTCPJ56.SGD","IXJ","LU0823434740.USD","LU0225283273.USD","IE00BN29S564.USD","IE00B2B36J28.USD","SG9999014880.SGD","LU0820562030.AUD","ELIS","LU0109391861.USD","LU0354030511.USD","LU2471134523.USD","RXL","LU0823434583.USD","SG9999015978.USD","LU1989771016.USD","IE00B1XK9C88.USD","LU0820561818.USD","LU0058720904.USD","LU0266013472.USD","LU0882574139.USD","LU0353189763.USD","LU0708995401.HKD","LU2237443622.USD","LU0061475181.USD","LU1069344957.HKD","LU0114720955.EUR","LU1868837136.USD","LU2023250330.USD","LU0079474960.USD","LU2896262040.SGD","IE00BKPKM429.USD","SG9999015945.SGD","LU0109394709.USD","IE00B1BXHZ80.USD","LU2237443895.HKD","MHIP","LU2471134796.USD","SG9999018857.SGD","IE00B775H168.HKD","IE0002141913.USD","SGXZ81514606.USD","LU2602419157.SGD","PJP","LU0158827948.USD","AGNG","LU0094547139.USD","LU0345770308.USD","LU2462157665.USD","LU2028103732.USD","LU2089284900.SGD","LU2237443465.HKD","LU2756315664.SGD","LU0256863902.USD","LU2361045086.USD","SG9999001176.SGD","LU2491050071.SGD","MEDI","LU1064131342.USD","LU0210536198.USD","LU1267930730.SGD","IE00BJLML261.HKD","LU2750360997.AUD","LU2552382215.SGD","SG9999015952.SGD","THNR","LU0786609619.USD","LU1291159041.SGD","BK4581","LU2471134952.CNY","BK4007","LU1127390331.HKD","LU1551013342.USD","IE00BJJMRY28.SGD","IE00B7KXQ091.USD","GDOC","BK4533","LU0683600562.USD","LU2237443978.SGD","LU2111349929.HKD","LU2087625088.SGD","LU0106261372.USD","LU2168563687.JPY","LU2237443382.USD","BK4588","LU0353189680.USD","LU1023059063.AUD","LU0174119429.USD","LU1232071149.USD","LU1093756168.USD","LU1691799644.USD","SG9999014898.SGD","LU1548497426.USD","ELIL","IE00BJJMRZ35.SGD","LU0238689110.USD","LU2106854487.HKD","LU0354030438.USD","LU0432979614.USD","LU0820561909.HKD","LU0320765992.SGD","LU1035775433.USD","LU2168564065.EUR","LU2361044865.SGD","LU0417517546.SGD","IE0009355771.USD","LU0158827781.USD","LU2491049909.HKD","LU0122379950.USD","LU1720051017.SGD","LU2063271972.USD","IE00BFSS7M15.SGD","BK4599","LU0787776722.HKD","LU1988902786.USD","LU2361044949.HKD","IE00BK4W5L77.USD","LU0006306889.USD","LU1917777945.USD","IE00B4R5TH58.HKD","LU1868837300.USD","SG9999001176.USD","LU0640476718.USD","IE00BJT1NW94.SGD","LU2023251221.USD","LU1057294990.SGD","JDOC","LU2468319806.SGD","SG9999017495.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666599172","title":"Eli Lilly’s GLP-1 Windfall to Fund Push into Women’s Health - Bloomberg News","url":"https://stock-news.laohu8.com/highlight/detail?id=2666599172","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666599172?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:54","pubTimestamp":1789048478,"startTime":"0","endTime":"0","summary":"MEDIA-Eli Lilly’s GLP-1 windfall to fund push into women’s health - Bloomberg News-- Source link: https://tinyurl.com/327fb793-- Note: Reuters has not verified this story and does not vouch for its accuracy","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nL6N4520XF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU0203202063.USD","LU1548497426.USD","LU2357305700.SGD","LU0820562030.AUD","LU0823416689.USD","LU0787776722.HKD","LU0094547139.USD","CANC","LU0353189680.USD","LU1035775433.USD","LU1280957306.USD","LU1291159041.SGD","LU1988902786.USD","LU2462157665.USD","LU1974910355.USD","IE00BJJMRX11.SGD","LU0345770993.USD","PPH","LU2023250330.USD","LU2361044865.SGD","LU2264538146.SGD","IE00BWXC8680.SGD","IE00BKDWB100.SGD","LLII","LU0256863811.USD","LU2168563687.JPY","LU0708995401.HKD","LU2211815571.USD","SG9999015986.USD","LLY","LU1814569148.SGD","LU2168564149.EUR","RXL","LU1323610961.USD","BK4007","LU1868836757.USD","IE0002141913.USD","SG9999001176.USD","SGXZ81514606.USD","LU1366192091.USD","LU2324357040.USD","LU1064131342.USD","LU0823434583.USD","IE00BKPKM429.USD","LU0097036916.USD","LU2552382058.USD","LU0672654240.SGD","IHE","LU2756315318.SGD","BK4516","JDOC","LU1623119135.USD","LU2023251221.USD","SG9999014914.USD","LU0823434740.USD","LU2361045086.USD","IE0004445015.USD","IE00BJLML261.HKD","LU0354030438.USD","LU2471134952.CNY","IE00BJJMRZ35.SGD","LU2265009873.SGD","LU1868836591.USD","XLV","LU1023059063.AUD","LU1551013342.USD","LU2168564495.EUR","LU2237443382.USD","LU0471298694.HKD","LU0006306889.USD","LU2602419157.SGD","LU1267930730.SGD","IE00BJJMRY28.SGD","LU2237443895.HKD","LU0353189763.USD","IE00BK4W5M84.HKD","THNR","LU0109391861.USD","LU0238689110.USD","LU0323591593.USD","LU2063271972.USD","LU2461242641.AUD","LU2896262040.SGD","LU0158827948.USD","LU2089284900.SGD","MEDI","LU2360106947.USD","LU0174119429.USD","LU0203201768.USD","LU1720051017.SGD","BK4599","IE00B1XK9C88.USD","LU0225283273.USD","LU2023250504.SGD","MHIP","LU0964807845.USD","LU1629891620.HKD","LU1868836914.USD","LU1069344957.HKD","LU2237443465.HKD","BK4581","LU2237443622.USD","LU0432979614.USD","LU2491050071.SGD","IE00B2B36J28.USD","SGXZ57979304.SGD","LU0109394709.USD","LU1989771016.USD","IE00BFSS8Q28.SGD","IE00B775H168.HKD","LU0882574139.USD","LU1979441026.SGD","TRUH","BK4534","ILDR","LU0354030511.USD","GB00BDT5M118.USD","LU2213496289.HKD","LU1720051108.HKD","IE00BN29S564.USD","BK4533","LU0061475181.USD","LU0882574055.USD","SG9999017495.SGD","IE00B4R5TH58.HKD","LU0266013472.USD","LU2112291526.USD","PJP","LU2168564222.USD","LU0417517546.SGD","SG9999014880.SGD","LU2417539215.USD","LU1983299246.USD","LU0316494557.USD","LU1868837300.USD","LU1868837136.USD","LU2028103732.USD","LU1093756168.USD","SG9999015945.SGD","SG9999018865.SGD","SGXZ99366536.SGD","IE00B4JS1V06.HKD","LU1917777945.USD","IE0001KFT4U8.USD","LU0133085943.USD","MEDX","IE0009355771.USD","LU2237443549.SGD","LU0456855351.SGD","HRTS","LU2087625088.SGD","LU2491049909.HKD","LU2746668461.USD","SG9999014906.USD","LU1691799644.USD","VHT","IE00BJT1NW94.SGD","LU0385154629.USD","LU2456880835.USD","LU1061106388.HKD","LU2236285917.USD","GDOC","LU0320765059.SGD","LU2552382132.HKD","FTXH","IE0005OL40V9.USD","LU0820561909.HKD","LU1712237335.SGD","LU2111349929.HKD","SG9999014898.SGD","SGXZ51526630.SGD","LU2552382215.SGD","IE00BFSS7M15.SGD","LU2168564065.EUR","LU2746668974.SGD","LU0234572021.USD","LU0210536198.USD","LU2361044949.HKD","LU0320765992.SGD","LU1127390331.HKD","LU1093756325.SGD","AGNG","LU1804176565.USD","LU0943347566.SGD","LU0058720904.USD","CURE","IYH","LU0471298777.SGD","LU0786609619.USD","LU0640476718.USD","LU2750360997.AUD","IXJ","LU1551013425.SGD","LU0289739699.SGD","SG9999015978.USD","SGXZ31699556.SGD","LU0198837287.USD","LU2491050154.USD","BK4588","LU0889565916.HKD","BK4585","LU0079474960.USD","LU0096364046.USD","LU1145028129.USD","IE00B7KXQ091.USD","LU2750360641.GBP","LU1057294990.SGD","LU0122379950.USD","SG9999013999.USD","LU2468319806.SGD","FHLC","LU2237438978.USD","WDNA","LU0466842654.USD","LU2089283258.USD","TMED","LU2237443978.SGD","SG9999001176.SGD","LU0256863902.USD","SG9999015952.SGD","LU0683600562.USD","LU2756315664.SGD","LU2271345857.HKD","SG9999018857.SGD","LU0106261372.USD","LU2471134879.HKD","IE00B1BXHZ80.USD","IE0004445239.USD","IE00BK4W5L77.USD","LU0345770308.USD","LU0820561818.USD","ELIL","ELIS","OZEM","LU0158827781.USD","LU1232071149.USD","LU2089984988.USD","LU2106854487.HKD","LU2462591350.SGD","LLYZ","LU2471134523.USD","LU0689472784.USD","LLYX","LU2471134796.USD","LU2108987350.USD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666159950","title":"Novartis shareholder calls for board changes, Reuters reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2666159950","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666159950?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:30","pubTimestamp":1789047012,"startTime":"0","endTime":"0","summary":"A major Novartis (NVS) shareholder is calling for board changes following successive clinical setbacks and concerns over the company’s acquisition ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-shareholder-calls-for-board-changes-reuters-reports-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-shareholder-calls-for-board-changes-reuters-reports-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0208291251.USD","BK4588","MEDX","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0070302665.USD","NVS","LU0211331839.USD","IE00BFTCPJ56.SGD","PPH","BK4532","IE0002141913.USD","BK4007","BK4585","IE0009355771.USD","IE00B2B36J28.USD","LU0320765489.SGD","IE00B4R5TH58.HKD","BK4578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666596073","title":"AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2666596073","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666596073?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:30","pubTimestamp":1789047005,"startTime":"0","endTime":"0","summary":"AbbVie (ABBV) said Thursday that atogepant for the preventive treatment of menstrual migraine in adults met its primary and all eight ranked secondary endpoints in the Phase 3 LUNA study.Atogepant dem","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IXJ","FTXH","IE00BLSP4452.SGD","BK4139","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LU0985320562.USD","SG9999001440.SGD","TRUH","LU1934455863.HKD","AGNG","ABBV","LU0965509101.SGD","LU0912757837.SGD","VHT","LU0211328371.USD","IE0004445239.USD","LU1496350171.SGD","PPH","LU0456855351.SGD","PJP","GLAM","RXL","SG9999003800.SGD","SG9999015986.USD","LU0395794307.EUR","LU0029864427.USD","LU0882574055.USD","LU1037948897.HKD","LU1244550577.SGD","LU2129689514.USD","LU0820561818.USD","LU2347655156.SGD","IYH","IE00BVYPNV92.GBP","IE00BLSP4239.USD","LU2125909247.SGD","LU0708994859.HKD","LU2237443622.USD","JDOC","LU1244550221.USD","LU1236620834.HKD","BK4534","IE00BJT1NW94.SGD","LU0820561909.HKD","XLV","LU1061106388.HKD","FHLC","MEDX","LU0511384066.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666599595","title":"IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2666599595","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666599595?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:30","pubTimestamp":1789047000,"startTime":"0","endTime":"0","summary":"Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimens IMUNON retains ownership of its background intellectual property wit","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/10/3359640/0/en/imunon-enters-cooperative-research-and-development-agreement-with-national-cancer-institute-to-advance-clinical-development-of-imnn-001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN","IDNA","BK4139","MEDX","NVIB","GDOC","NCI","HYLG","NHLD","BK4202"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666596813","title":"AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine","url":"https://stock-news.laohu8.com/highlight/detail?id=2666596813","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666596813?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:00","pubTimestamp":1789045214,"startTime":"0","endTime":"0","summary":"AbbVie (ABBV) announced positive topline results from the Phase 3 LUNA study, which evaluated atogepant, a calcitonin gene-related peptide, or CGRP...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abbvies-atogepant-shows-positive-phase-3-results-in-menstrual-migraine-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abbvies-atogepant-shows-positive-phase-3-results-in-menstrual-migraine-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1236620834.HKD","FTXH","LU0965508806.USD","LU1057294990.SGD","LU2237443465.HKD","IE00BN8TJ469.HKD","IE00BSNM7G36.USD","IE0000B7K699.USD","AGNG","LU0128525929.USD","MEDX","LU0823416689.USD","LU0859254822.USD","LU2089984988.USD","IE00BFTCPJ56.SGD","LU0170899867.USD","LU2357627491.SGD","LU0795875086.SGD","LU0949170772.SGD","LU1670628061.USD","PJP","PPH","LU0289739699.SGD","LU2237443382.USD","IE000MB6IJN5.SGD","VHT","ABBV","BK4550","BK4139","BK4588","IYH","LU1989772923.USD","IE00B2B36J28.USD","JDOC","LU0114720955.EUR","LU1934455863.HKD","LU0661504455.SGD","LU0553294199.USD","GLAM","BK4581","LU0203345920.USD","LU0726765562.USD","BK4534","IXJ","RXL","LU0256863811.USD","FHLC","IE00BBT3K403.USD","TRUH","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666954045","title":"Abbvie - Atogepant Safety Results Consistent with Known Profile; no New Safety Signals","url":"https://stock-news.laohu8.com/highlight/detail?id=2666954045","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666954045?lang=en_us&edition=fundamental","pubTime":"2026-09-10 20:55","pubTimestamp":1789044900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA8RPXBH:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1244550494.USD","LU0158827948.USD","LU1989772923.USD","LU1732800096.USD","LU0289739343.SGD","LU0949170772.SGD","TRUH","LU2125909593.SGD","IE000BZT7R73.USD","PJP","SG9999001440.SGD","ABBV","RXL","LU0417517546.SGD","LU1496350171.SGD","LU1267930573.SGD","BK4559","PPH","IYH","SG9999015978.USD","LU0820561909.HKD","LU0545039389.USD","AGNG","MEDX","VHT","LU0456855351.SGD","LU1291159041.SGD","LU1929549753.HKD","LU0289961442.SGD","IE00BN8TJ469.HKD","IE00BDGV0183.EUR","LU1934455194.USD","LU2433249047.HKD","LU2133065610.SGD","IE00BGHQF631.EUR","LU2125909247.SGD","SG9999015986.USD","FHLC","LU0726765562.USD","FTXH","JDOC","IE00BLSP4239.USD","XLV","IXJ","LU0689626769.HKD","GLAM","LU0965508806.USD","LU0170899867.USD","BK4581","LU0124676726.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666595402","title":"Abbvie - Atogepant Meets Primary and All Eight Ranked Secondary Endpoints in Phase 3 Luna Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2666595402","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666595402?lang=en_us&edition=fundamental","pubTime":"2026-09-10 20:55","pubTimestamp":1789044900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA8RPXBH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGNG","IYH","LU0158827948.USD","LU1244550221.USD","PPH","IE000BZT7R73.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU1496350502.SGD","LU1670628061.USD","LU1934455194.USD","LU2089984988.USD","LU0417517546.SGD","TRUH","XLV","LU0795875169.SGD","LU0820561909.HKD","LU1718418525.SGD","JDOC","MEDX","FHLC","LU2347655156.SGD","VHT","LU1732800096.USD","PJP","BK4559","IE0004445239.USD","LU0395794307.EUR","IE00B3PB1722.GBP","LU1983299246.USD","LU0432979614.USD","LU2237443549.SGD","ABBV","LU0203347892.USD","LU1244550577.SGD","LU0122379950.USD","LU1551013425.SGD","LU0965509010.AUD","FTXH","LU1934455863.HKD","LU0553294199.USD","IXJ","LU1037948897.HKD","GLAM","LU2089283258.USD","IE00B42XCP33.USD","RXL","LU1093756168.USD","IE00B2B36J28.USD","LU0472753341.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666595401","title":"Abbvie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine","url":"https://stock-news.laohu8.com/highlight/detail?id=2666595401","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666595401?lang=en_us&edition=fundamental","pubTime":"2026-09-10 20:55","pubTimestamp":1789044900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA8RPXBH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2237443382.USD","LU2089984988.USD","LU2237443465.HKD","LU0203345920.USD","LU0553294199.USD","PJP","IE00B2B36J28.USD","LU0949170772.SGD","LU0661504455.SGD","LU1934455863.HKD","LU1236620834.HKD","LU0170899867.USD","LU1057294990.SGD","BK4534","JDOC","IYH","ABBV","BK4588","LU0256863811.USD","PPH","IE0000B7K699.USD","BK4581","BK4550","LU0114720955.EUR","IE00BN8TJ469.HKD","RXL","IE00BFTCPJ56.SGD","LU0128525929.USD","BK4139","LU0726765562.USD","LU0965508806.USD","FTXH","IE000MB6IJN5.SGD","VHT","IE00BSNM7G36.USD","MEDX","LU0289739699.SGD","IXJ","LU2357627491.SGD","IE00BBT3K403.USD","AGNG","GLAM","LU0795875086.SGD","LU1989772923.USD","LU0859254822.USD","LU0823416689.USD","TRUH","LU1670628061.USD","FHLC","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666059540","title":"Abbvie - Atogepant Shows Significant Improvements Across Multiple Endpoints Versus Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2666059540","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666059540?lang=en_us&edition=fundamental","pubTime":"2026-09-10 20:55","pubTimestamp":1789044900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA8RPXBH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE000SO60NU8.SGD","XLV","AGNG","LU1839511570.USD","PJP","LU1496350502.SGD","IE00B3PB1722.GBP","LU1732800096.USD","LU0545039389.USD","LU2089284900.SGD","LU0289739343.SGD","IE00B19Z3B42.SGD","JDOC","LU2133065610.SGD","IE0002141913.USD","BK4585","IXJ","LU0868494708.USD","VHT","IE0004445239.USD","IYH","TRUH","ABBV","LU0820561818.USD","BK4534","FHLC","LU1162221912.USD","LU1923622614.USD","IE0009355771.USD","IE000BZT7R73.USD","LU1732799900.SGD","LU2237443622.USD","PPH","IE0000B7K699.USD","LU0417517546.SGD","LU0472753341.HKD","LU1934455194.USD","LU2468319806.SGD","IE00BVYPNW00.USD","GLAM","LU1983299246.USD","LU0128525929.USD","LU1989771016.USD","RXL","MEDX","SG9999001440.SGD","FTXH","LU2125909247.SGD","LU2129689431.USD","IE00BBT3K403.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666598426","title":"Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX","url":"https://stock-news.laohu8.com/highlight/detail?id=2666598426","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666598426?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:50","pubTimestamp":1789041051,"startTime":"0","endTime":"0","summary":"Johnson & Johnson has received CE Marking for ACUVUE OASYS MAX 2-Week, a new reusable contact lens featuring proprietary MAX technologies designed ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/johnson-johnson-receives-ce-marking-for-acuvue-oasys-max-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/johnson-johnson-receives-ce-marking-for-acuvue-oasys-max-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","SGXZ57979304.SGD","BK4078","IE00B7SZLL34.SGD","LU2750360641.GBP","LU0345770308.USD","TRUH","IE00B3PB1722.GBP","IE000M9KFDE8.USD","LU1228905037.USD","MAX","IE00B2B36J28.USD","SG9999002232.USD","IE00BVYPNW00.USD","MEDX","IE0000B7K699.USD","LU1929549753.HKD","LU0345769631.USD","LU2471134952.CNY","LU0203347892.USD","LU0689626769.HKD","IE00BDGV0183.EUR","GPRO","PJP","IE00BLSP4452.SGD","JDOC","IE00BSNM7G36.USD","BK4533","BK4559","LU0320765646.SGD","LU0787776722.HKD","VHT","LU1894683264.USD","RXL","JNJ","LU0234570918.USD","LU1066053197.SGD","IHE","FHLC","BK4581","BMED","XLV","IYH","LU1032955483.USD","LU0943347566.SGD","LU1280957306.USD","IE000MB6IJN5.SGD","FTXH","IXJ","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666598612","title":"Market Chatter: Novartis Shareholder Urges Board Changes After Trial Failures","url":"https://stock-news.laohu8.com/highlight/detail?id=2666598612","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666598612?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:47","pubTimestamp":1789040824,"startTime":"0","endTime":"0","summary":"Novartis  shareholder Artisan Partners called for changes to the Swiss drugmaker's board following two consecutive drug trial setbacks that sent shares tumbling, Reuters reported Thursday, citing an interview with Artisan managing director David Samra.Novartis needs stronger oversight of acquisitions, citing the $12 billion Avidity deal and the 2024 MorphoSys acquisition, which was later written down, Samra told ReutersSamra questioned the board's acquisition oversight, while Novartis reaffirmed its unchanged guidance and focus on disciplined capital allocation and shareholder returns, Reuters added.Novartis shares were up 1.7% in premarket activity.Novartis did not immediately respond to MT Newswires' request for comment.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVS","BK4585","IE00BJT1NW94.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU0208291251.USD","BK4588","LU0070302665.USD","IE00BFTCPJ56.SGD","LU0320765489.SGD","BK4007","IE00B2B36J28.USD","BK4578","BK4532","PPH","MEDX","IE0009355771.USD","LU0211331839.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666598631","title":"Johnson & Johnson Receives Ce Marking for Acuvue Oasys Max Reusable Contact Lenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2666598631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666598631?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:45","pubTimestamp":1789040700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA26VGSH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B4R5TH58.HKD","GDOC","LU1043141396.HKD","IE00BLSP4239.USD","LU0320765646.SGD","LU1032955483.USD","MEDX","BK4559","IE00BFXG1179.USD","IYH","JNJ","LU0432979614.USD","BMED","LU0058720904.USD","IE00BBT3K403.USD","LU1506573853.SGD","JDOC","LU0466842654.USD","LU1261432733.SGD","IE000WAW04H5.SGD","IE00BJT1NW94.SGD","LU2129689605.HKD","FTXH","LU2592432038.USD","IHE","FHLC","LU1894683264.USD","BK4550","IXJ","XLV","RXL","LU1935042991.SGD","LU2089984988.USD","LU1057294990.SGD","LU2602419157.SGD","LU2023250330.USD","IE00BVYPNW00.USD","LU2487616109.SGD","SGXZ57979304.SGD","VHT","LU1280957306.USD","LU2750360641.GBP","TRUH","LU1291159041.SGD","PJP","LU1032466523.USD","BK4533","LU0345770308.USD","LU1074936037.SGD","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666598627","title":"CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2666598627","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666598627?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:33","pubTimestamp":1789039980,"startTime":"0","endTime":"0","summary":"Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina Com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/10/3359400/0/en/camp4-therapeutics-receives-authorization-in-the-united-kingdom-for-phase-1-2-human-clinical-trial-of-cmp-002-in-patients-with-syngap1-related-disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4200","BK4139","CMP","NVIB","BK4007","MEDX","UBCP","BK4211","LENZ","ASO","BK4561","HYLG","IDNA","BK4168","GDOC","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666567022","title":"Alkermes Announces Launch of 9TH Annual Alkermes Pathways Research Awards® Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2666567022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666567022?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:00","pubTimestamp":1789038000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA8WKBZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","BK4139","MEDX","IBRN","ALKS","FBT","PSIL"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":2,"totalSize":296,"code":"91000000","status":"200"}]}}